Patents by Inventor Igor Splawski

Igor Splawski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for antibodies targeting EPO
    Patent number: 9365646
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: June 14, 2016
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20160031975
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: April 28, 2015
    Publication date: February 4, 2016
    Applicant: NOVARTIS AG
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P
    Publication number: 20150158936
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Application
    Filed: June 19, 2014
    Publication date: June 11, 2015
    Applicant: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester KUNZ, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • Antibodies that bind factor P
    Patent number: 9051365
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Sha-Mei Liao, Michael Stefanidakis
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20150004168
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: January 1, 2015
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Compositions and methods for antibodies targeting complement protein C5
    Patent number: 8883158
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: November 11, 2014
    Assignee: Novartis AG
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
    Publication number: 20140199306
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Application
    Filed: December 3, 2013
    Publication date: July 17, 2014
    Applicant: NOVARTIS AG
    Inventors: Joy GHOSH, Mark Anthony RUTZ, Katrin Ulrike TISSOT-DAGUETTE, Igor SPLAWSKI, Michael ROGUSKA
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P
    Publication number: 20130295102
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Application
    Filed: December 17, 2012
    Publication date: November 7, 2013
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20130064836
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: July 25, 2012
    Publication date: March 14, 2013
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20130022615
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: June 28, 2012
    Publication date: January 24, 2013
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • Compositions and methods for antibodies targeting complement protein C5
    Patent number: 8241628
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: August 14, 2012
    Assignee: Novartis AG
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C3B
    Publication number: 20100291106
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind to both human and cynomolgus complement protein C3b, as well as compositions and methods of use thereof.
    Type: Application
    Filed: May 4, 2010
    Publication date: November 18, 2010
    Inventors: Bijan Etemad-Gilbertson, Braydon Charles Guild, Yong-In Kim, Ingo Klagge, Alexandra Kraus, Michael Roguska, Igor Splawski, Kehao Zhao
  • C5 Antigens and Uses Thereof
    Publication number: 20100166748
    Abstract: The present invention pertains to the use of a complement inhibitor in methods of treatment of ocular disorders and the use of a complement inhibitor in the manufacture of a medicament in the treatment of an ocular disorder.
    Type: Application
    Filed: March 19, 2008
    Publication date: July 1, 2010
    Inventors: Braydon Charles Guild, Mark Taylor Keating, Mariusz Milik, Dmitri Mikhailov, Michael Roguska, Igor Splawski, Kehao Zhao
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20100034809
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: August 4, 2009
    Publication date: February 11, 2010
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
  • Molecules and Methods for Modulating Complement Component
    Publication number: 20090175875
    Abstract: Compositions that bind to C3b epitopes and methods of using the compositions are described herein.
    Type: Application
    Filed: November 3, 2008
    Publication date: July 9, 2009
    Inventors: Bijan ETEMAD-GILBERTSON, Braydon Charles Guild, Mark Taylor Keating, Yong-In Kim, Lloyd B. Klickstein, Dmitri Mikhailov, Mariusz Milik, Michael Roguska, Igor Splawski, Kehao Zhao
  • Mutations in and genomic structure of —a long QT syndrome gene
    Patent number: 7297489
    Abstract: The invention relates to the determination of the genomic structure of HERG which is a gene associated with long QT syndrome. The sequences of the 15 intron/exon junctions has been determined and this information is useful in devising primers for amplifying and sequencing across all of the exons of the gene. This is useful for determining the presence or absence of mutations which are known to cause long QT syndrome. Also disclosed are many new mutations in HERG which have been found to be associated with long QT syndrome.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: November 20, 2007
    Assignee: University of Utah Research Foundation
    Inventors: Mark Keating, Igor Splawski
  • Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
    Patent number: 7247436
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: July 24, 2007
    Assignee: University of Utah Research Foundation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Igor Splawski
  • Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia
    Patent number: 7208273
    Abstract: The present invention is directed to a specific mutation in SCN5A which causes drug-induced torsade de pointes or ventricular fibrillation. Persons with the mutation are predisposed to developing drug-induced torsade de pointes or ventricular fibrillation when administered certain drugs. This predisposition can be diagnosed in accordance with the present invention by analyzing the DNA sequence of the SCN5A of an individual. By screening patients for the mutation, drug-induced torsade de pointes or ventricular fibrillation can be avoided. Furthermore, drugs can be tested to determine whether they will cause torsade de pointes or ventricular fibrillation.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: April 24, 2007
    Assignee: University of Utah Research Foundation
    Inventors: Mark T. Keating, Igor Splawski
  • KVLQT1—a long QT syndrome gene
    Patent number: 6972176
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: December 6, 2005
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski, Qing Wang
  • MinK-related genes, formation of potassium channels and association with cardiac arrhythmia
    Patent number: 6864364
    Abstract: The present invention is directed to genes and gene products related to Min-K which form ion channels and to a process for diagnosis of ion channel disorders, including long QT syndrome (LQT). For example, KCNE2 forms IKr potassium channels and is associated with LQT. LQT is diagnosed in accordance with the present invention by analyzing the DNA sequence of KCNE2 of an individual to be tested and comparing the respective DNA sequence to the known DNA sequence of a normal KCNE2 gene. Alternatively, these MinK-related genes of an individual to be tested can be screened for mutations which cause ion channel disorders, including LQT. Prediction of ion channel disorders, including LQT, will enable practitioners to prevent the disorders using existing medical therapy. This invention is further directed to the discovery that the HERG and KCNE2 (also known as MiRP1) proteins coassemble to form a cardiac IKr potassium channel.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: March 8, 2005
    Assignees: University of Utah Research Foundation, Yale University
    Inventors: Igor Splawski, Mark T. Keating, Geoffrey W. Abbott, Federico Sesti, Steve A. N. Goldstein